



SIRIUS NEOSIGHT

PRESS RELEASE

Lyon, February 4th, 2025

SIRIUS NEOSIGHT completes a €4.4 million funding round to support the development of its therapeutic prediction technology platform in oncology

SIRIUS NEOSIGHT, a company specializing in the isolation of Circulating Tumor Cells (CTCs) and the development of functional tests for predicting therapeutic response in oncology, has completed a €4.4 million funding round. The financing round was secured from GO CAPITAL via its GOCA3 seed fund, DEMETER through the FAIM (Fonds d'Amorçage Industriel Métropolitain) Lyon/Saint-Etienne fund, as well as Evolem, Crédit Agricole Création, Octalfa, Angel Santé, Better Angle, and business angels specializing in life sciences. This funding will accelerate the development of its personalized medicine platform, ultimately aiming to provide the most effective targeted treatment for each patient.

The funding round is also supported by a banking pool and grants obtained from Bpifrance. Sirius is proud to count key clinical oncology players among its stakeholders, including the Centre Léon Bérard in Lyon (via Lyon Berard Innovation) and the Institut de Cancérologie de l'Ouest (ICO via ICO Innov).

Sirius Neosight : A patented technology for personalized therapeutic guidance in oncology

Founded in late 2023, Sirius Neosight is a spin-off from the Centre Léon Bérard in Lyon and academic laboratories : Centre de Recherche de Cancérologie de Lyon (CRCL : Université Claude Bernard Lyon 1, Inserm, Centre Léon Bérard, CNRS) and l'Institut de Chimie et Biochimie Moléculaires et Supramoléculaires (ICBMS : Université Claude Bernard Lyon 1, INSA Lyon, CPE Lyon et CNRS). It builds upon research conducted by Pr Arnaud Vigneron and Pr David Gueyrard, both inventors of the technology and co-founders of the company, alongside Agnès Bastid, CEO of Sirius Neosight. The initial developments were partially funded by maturation programs supported by SATT Pulsalys and CNRS. Sirius Neosight subsequently received the French Tech Emergence grant from Bpifrance and was a winner of the i-Lab 2024 competition. These early financial supports enabled the filing of initial patents related to membrane fluidity measurement technology, which allows for the universal and highly

precise isolation of Circulating Tumor Cells from a simple blood sample and the first proof-of-concept for its treatment efficacy prediction platform.

With this first round of funding, Sirius aims to further its ambitions by offering new perspectives in oncology. Over the next two years, financial resources will be used to develop a biological production platform and therapeutic prediction tests that precisely guide the functional response of targeted therapies for each patient from a simple blood sample. A first clinical demonstrator is set to launch in 2025 in partnership with the Centre Léon Bérard in Lyon, and new targets are also under preclinical development.

Operational and clinical development will expand beyond the Auvergne-Rhône-Alpes region starting in early 2025, with the strategic registration of a secondary operational facility in the Grand-Ouest region and the establishment of a close partnership with the Institut de Cancérologie de l'Ouest (ICO) and the Prot'ICO Platform, key players in cancer research.

« We are delighted with the confidence shown by our investors. Their support, along with that of the national ecosystem, is crucial for our development. I am very proud to work every day alongside the dedicated teams at Sirius Neosight. Based at the Centre Léon Bérard, Sirius Neosight aims to quickly bring new solutions to cancer patients, and we are fully committed to improving patient care with the hope of a faster and more effective treatment approach. » declared **Agnès Bastid, President and co-founder of Sirius Neosight**

« GO CAPITAL, through its GOCA3 seed fund, is proud to join Sirius Neosight and to provide financial and strategic support for this new approach in oncology. Sirius Neosight's solution addresses a real need for more targeted therapy to better treat all patients. The project's ambition, backed by a strong team and its presence in our western regions, convinced us to invest, » stated **Leïla Nicolas, Partner specializing in healthcare at GO Capital, lead investor in this funding round.**

« The innovation developed by Sirius Neosight will have a truly positive impact on the care of cancer patients by allowing them to directly benefit from the most effective treatment in a personalized care pathway. This biological production platform and testing project in the Lyon region aligns perfectly with the strategy of the FAIM fund managed by Demeter. We are very pleased to support this high-quality team, » declared **Céline Charvin, Investment Director at Demeter.**

About Sirius Neosight: www.sirius-neosight.com



Sirius Neosight develops a membrane fluidity measurement technology capable of universally and highly efficiently discriminating and purifying Circulating Tumor Cells (CTCs) present in the bloodstream. Sirius' technology aims to revolutionize early relapse detection, treatment resistance analysis in oncology, and the identification of personalized therapies for the most aggressive cancers.

About GO Capital : www.gocapital.fr



GO Capital is an independent investment management company and a key player in impact investing. With nearly €400 million under management, we primarily finance technological leaders in the digital, healthcare, and climate transition sectors. Our team of investors, with complementary sectoral expertise, focuses on two verticals: territorial impact and sectoral impact. We support innovative and responsible projects, creating sustainable value at the heart of regions and key industries. The GOCA3 fund, with €47 million, plays a major role in financing innovative and technological projects in the Grand-Ouest region.

About DEMETER : www.demeter-im.com



Demeter is a major European investment firm specializing in venture capital, growth capital, and infrastructure investments in energy and ecological transition. Its funds invest between €1 million and €30 million to support companies in the sector at all stages of their development, from innovative startups to SMEs and infrastructure projects. With a team of 38 people based in Paris, Lyon, Bordeaux, Madrid, and Düsseldorf, Demeter manages €1.3 billion and has made 230 investments since 2005. The Lyon team manages the FAIM fund.

About FAIM Lyon – Saint-Etienne : www.demeter-im.com/faim/

The FAIM (Fonds d'Amorçage Industriel Métropolitain) is a seed and venture capital fund designed to support high-social or environmental-impact productive activities in the metropolitan areas of Lyon and Saint-Etienne. With €70 million in funding, it benefits from the support of public actors, including contributions of €17 million from Lyon and €5 million from Saint-Etienne, as well as €10 million from Banque des Territoires, as part of France 2030's "Territories of Innovation" program. This fund also mobilizes numerous private investors, including industrial and institutional players. It is classified under Sustainable Finance Disclosure Regulation (SFDR) Article 9, the highest standard for sustainable investment.



Press contacts :

- Sirius NEOSIGHT : Agnès Bastid - CEO – a.bastid@sirius-ns.com
- GO CAPITAL : Leila NICOLAS – Partner – leila.nicolas@gocapital.fr
- DEMETER : Céline Charvin - celine.charvin@demeter-im.com
- PULSALYS : Sylvain DUC – sylvain.duc@pulsalys.fr

Sirius Neosight advisors :

- Legal advisor : Sandra Baverel
- Accounting, Tax and Social Affairs Advisors : CANOPEE Group - Quentin Driguzzi / ODICEO - Agnès Lamoine, Grégoire Varvier and Christophe Vincent
- Intellectual Property Advisors : LAURENT & CHARRAS - Anne Buchet and Esther Maitrejean

Investors advisors :

- Legal advisor : Cabinet FIDAL - Jacques Darbois and Anaïs Abchar
- Accounting, Tax and Social Affairs Advisors : Cabinet SECOB - Mathieu Le Barz and Cédric Guegan
- Intellectual Property : ICOSA - Claire Vershelde and Coline Trichot
- ESG advisor : GreenFlex - Camille Poutrin